ロード中...
Phase I/II Trial of Immunotherapy with Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early trial report
Current strategies to improve clinical outcomes in KRAS-mutant non-small cell lung cancer (NSCLC) patients include MEK inhibitor and PD-1 / PD-L1 immune checkpoint blockade (ICB) combinations. Experience from melanoma suggests that anti-CTLA-4 and anti-PD-1 / PD-L1 combinations improve outcomes, but...
保存先:
| 出版年: | Clin Lung Cancer |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7656492/ https://ncbi.nlm.nih.gov/pubmed/32299768 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2020.02.019 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|